Mochida Pharma Anti-Depression Drug MHD-55 Enters Phase III Trial
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Mochida Pharma announced that anti-depression drug MHD-55 (escitalopram) has entered Phase III trials. The company's pulmonary arterial hypertension drug MD-0701 (treprostinil), and a cell drug jointly developed with Japan Chemical Research Pharma will enter clinic trials this year. Mochida also plans to start Beselna Cream (imiquimod) clinic trials for additional applications of treating solar kerasotes. Currently imiquimod is a therapeutic agent for condyloma acuminatum. As part of its growth strategy, Mochida has been actively seeking and in-licensing products that have been marketed overseas to add to the company's product lineup. (Click here for more - Japanese language)
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.